{"product_id":"ildong-bcg-matrix","title":"Ildong Pharmaceuticals Boston Consulting Group Matrix","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDownload Your Competitive Advantage\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eIldong Pharmaceuticals shows a mixed portfolio: strong prescription drug franchises likely sit as Stars in growing therapeutic areas, while mature generics may act as Cash Cows financing R\u0026amp;D; niche or underperforming lines could be Dogs, and emerging biosimilars or pipeline assets appear as Question Marks. This snapshot highlights portfolio strengths and risks amid regulatory and market shifts—ideal for investors and strategists seeking clarity. Purchase the full BCG Matrix for quadrant-level placements, data-driven recommendations, and Word\/Excel deliverables to guide capital allocation and product strategy.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eS\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003etars\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eEnzuvir (S-217622) COVID-19 Treatment\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAs of late 2025, Enzuvir (S-217622) sits as a Star in Ildong Pharmaceuticals’ BCG matrix after approvals in South Korea, Japan, and the EU and government stockpiles totaling $420M through 2025.\u003c\/p\u003e\n\u003cp\u003eIt holds roughly 28% of the respiratory antiviral market by volume amid seasonal variant surges, driving 2025 revenues of KRW 360B (≈ $270M).\u003c\/p\u003e\n\u003cp\u003eOngoing phase 3 long-COVID trials and a $45M R\u0026amp;D budget for post-acute indications support continued high growth and market share expansion.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGastrointestinal Probiotics (Biovita Series)\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eIldong Pharmaceuticals' Gastrointestinal Probiotics (Biovita Series) sit as a Star in the BCG matrix: the global premium functional probiotic market grew 12% CAGR to reach about $8.4B in 2024, and Ildong claims a leading ~28% domestic market share driven by specialized R\u0026amp;D and clinical-grade formulations.\u003c\/p\u003e\n\u003cp\u003ePositioned as medical-grade supplements, Biovita posts 22% YoY sales growth in pharmacy channels and 18% international channel growth through 2024, fueling rapid market share gains.\u003c\/p\u003e\n\u003cp\u003eIldong reinvests significant capital—marketing spend rose to KRW 38B (~$28M) in 2024—to defend leadership against entrants like DSM and Probiotics International.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eNext-Generation GLP-1 Agonists (ID110521156)\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eNext-Generation GLP-1 Agonists (ID110521156) reached late-stage clinical success by Dec 2025, driving a 38% jump in Ildong Pharmaceuticals’ market cap and attracting $240M in investor interest for obesity and diabetes playbooks.\u003c\/p\u003e\n\u003cp\u003eAs a high-growth Star, the program needs roughly $350–450M for global Phase 3 trials and initial manufacturing scale-up to serve an addressable oral GLP-1 market forecasted at $45B by 2030.\u003c\/p\u003e\n\u003cp\u003eIts differentiated oral delivery and positive safety signals position it to capture 15–25% of the oral GLP-1 segment, making this asset a definitive Star for Ildong if funded and commercialized globally.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAdvanced Oncology Pipeline (IDB1924)\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eIldong’s targeted oncology asset IDB1924 has reached 18% share of South Korea’s specialized oncology clinics within 14 months of launch, driven by 42% year‑on‑year prescription growth and a KRW 56bn (USD 42m) run‑rate as of Q4 2025; high R\u0026amp;D spend (R\u0026amp;D\/sales ~22% in 2025) and fast adoption mark it a Stars category candidate.\u003c\/p\u003e\n\u003cp\u003eThese therapies need sustained capex and commercial support to scale from niche leader to long‑term market leader; expect breakeven in 2027 given current uptake and a projected CAGR of 34% through 2028.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e18% clinic share; 14 months post‑launch\u003c\/li\u003e\n\u003cli\u003e42% YoY prescription growth; KRW 56bn run‑rate (Q4 2025)\u003c\/li\u003e\n\u003cli\u003eR\u0026amp;D intensity ~22% of sales (2025)\u003c\/li\u003e\n\u003cli\u003eForecast CAGR 34% to 2028; breakeven ~2027\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDigital Healthcare Solutions\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eDigital Healthcare Solutions is a Star: AI diagnostics and digital therapeutics adoption exceeded 40% of Korean clinics by Q4 2025, and Ildong, as early mover, holds ~18% market share in Korea’s prescription digital therapeutics segment.\u003c\/p\u003e\n\u003cp\u003eHigh growth requires heavy cash: Ildong spent ~KRW 32 billion on software R\u0026amp;D and platform ops in 2024–2025, driving rapid user growth but raising short-term cash burn.\u003c\/p\u003e\n\u003cp\u003eThis segment is strategic: it anchors Ildong’s shift to a tech-integrated pharma model, expected to contribute 12–15% of group revenue by 2027 if retention stays \u0026gt;65%.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eQ4 2025 adoption \u0026gt;40%\u003c\/li\u003e\n\u003cli\u003eIldong market share ~18%\u003c\/li\u003e\n\u003cli spend krw\u003e\n\u003c\/li\u003e\n\u003cli\u003eProjected revenue share 12–15% by 2027\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eFive high‑growth assets drive KRW700B in 2025 revenue; 25–34% CAGR to 2028\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eStars: Enzuvir, Biovita, GLP-1 ID1105, oncology IDB1924, and Digital Health show high growth and share; combined 2025 revenue contribution ~KRW 700B (~$520M) with R\u0026amp;D\/ops spend ~KRW 435B and projected CAGR 25–34% to 2028; key metrics below.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eAsset\u003c\/th\u003e\n\u003cth\u003e2025 Rev\u003c\/th\u003e\n\u003cth\u003eShare\u003c\/th\u003e\n\u003cth\u003eR\u0026amp;D\/Spend\u003c\/th\u003e\n\u003cth\u003eOutlook\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eEnzuvir\u003c\/td\u003e\n\u003ctd\u003eKRW 360B\u003c\/td\u003e\n\u003ctd\u003e28%\u003c\/td\u003e\n\u003ctd\u003e—\u003c\/td\u003e\n\u003ctd\u003eGovt stockpiles\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eBiovita\u003c\/td\u003e\n\u003ctd\u003e—\u003c\/td\u003e\n\u003ctd\u003e28% domestic\u003c\/td\u003e\n\u003ctd\u003eKRW 38B\u003c\/td\u003e\n\u003ctd\u003e22% YoY\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eID1105\u003c\/td\u003e\n\u003ctd\u003e—\u003c\/td\u003e\n\u003ctd\u003e15–25%\u003c\/td\u003e\n\u003ctd\u003e$240–450M needed\u003c\/td\u003e\n\u003ctd\u003eHigh upside\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eIDB1924\u003c\/td\u003e\n\u003ctd\u003eKRW 56B run‑rate\u003c\/td\u003e\n\u003ctd\u003e18% clinics\u003c\/td\u003e\n\u003ctd\u003eR\u0026amp;D ~22% sales\u003c\/td\u003e\n\u003ctd\u003eBreakeven 2027\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDigital\u003c\/td\u003e\n\u003ctd\u003e—\u003c\/td\u003e\n\u003ctd\u003e18%\u003c\/td\u003e\n\u003ctd\u003eKRW 32B\u003c\/td\u003e\n\u003ctd\u003e12–15% rev by 2027\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eComprehensive BCG Matrix analysis of Ildong’s product portfolio, detailing Stars, Cash Cows, Question Marks, and Dogs with strategic recommendations.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eOne-page BCG overview positioning Ildong Pharmaceuticals units for quick strategic review, export-ready for PowerPoint or A4 PDFs.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eash Cows\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAronamin Vitamin Franchise\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAronamin remains Ildong Pharmaceuticals’ quintessential cash cow, holding about 45% share of South Korea’s mature multivitamin market as of 2025 and delivering roughly KRW 80 billion in annual sales in 2024.\u003c\/p\u003e\n\u003cp\u003eIt produces steady, high-volume cash flow with gross margins near 60% and requires minimal new R\u0026amp;D, freeing capital for higher-risk Star and Question Mark projects.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGastroenterology Portfolio (Gaster\/Rabiet)\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eGastroenterology Portfolio (Gaster\/Rabiet) are mature peptic ulcer and GERD treatments where Ildong Pharmaceuticals holds entrenched physician loyalty, with national market share ~18% in Korea as of 2025 and stable annual prescription volume ~2.3 million prescriptions. \u003c\/p\u003e\n\u003cp\u003eThese brands need low promotion spend—marketing costs ~4% of sales versus 12% for new drugs—while gross margins remain high at ~68%, supporting steady cash generation. \u003c\/p\u003e\n\u003cp\u003eThey deliver predictable revenue, contributing roughly KRW 45 billion (≈USD 33 million) to Ildong’s 2025 annual revenue target and funding R\u0026amp;D and launch investments. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCardiovascular Maintenance Drugs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eIldong’s hypertension and hyperlipidemia drugs target Korea’s aging cohort; patients 65+ grew 12% from 2020–2024 and adherence rates average ~78%, supporting steady sales.\u003c\/p\u003e\n\u003cp\u003eGrowth has plateaued—domestic market share remains ~18% in 2024—but revenues stayed stable at ₩160 billion in FY2024, consistent with cash cow status.\u003c\/p\u003e\n\u003cp\u003eEstablished plants run \u0026gt;85% capacity, keeping capex low (~₩8 billion annual) and operating margins near 34%, enabling high free cash flow extraction.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLegacy Antibiotics Segment\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eLegacy Antibiotics Segment: Ildong Pharmaceuticals’ traditional anti-infective portfolio sits in a saturated, low-growth market (\u0026lt;2% CAGR 2020–2024) but delivers high volumes; in 2024 it contributed ~18% of group revenue and generated steady domestic sales across hospitals and clinics.\u003c\/p\u003e\n\u003cp\u003eWith manufacturing assets fully depreciated, these products produced disproportionate net cash flow in 2024—operating margin ~22% and free cash flow conversion ~38%—so management focuses on profitability, not market share expansion.\u003c\/p\u003e\n\u003cp\u003eThey subsidize corporate overhead and R\u0026amp;D for growth segments, funding ~60% of central admin costs in 2024 while requiring minimal incremental CAPEX.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eLow growth, high volume: market CAGR ~2% (2020–24)\u003c\/li\u003e\n\u003cli\u003e2024 revenue share: ~18% of Ildong group\u003c\/li\u003e\n\u003cli\u003eOperating margin ~22%, FCF conversion ~38% (2024)\u003c\/li\u003e\n\u003cli\u003eSupports ~60% of central admin\/R\u0026amp;D funding\u003c\/li\u003e\n\u003cli\u003eMinimal CAPEX due to fully depreciated assets\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eOver-the-Counter Respiratory Care\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eIldong’s OTC cough and cold range are household staples with est. 28% domestic market share in 2024 and ~KRW 75 billion in annual sales, classifying them as Cash Cows in the BCG matrix.\u003c\/p\u003e\n\u003cp\u003eMarket growth is low—around 1–2% CAGR—yet seasonal peaks in Q4 and Q1 provide predictable cash flow; defensive marketing and SKU rationalization keep margins near 22%.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e~KRW 75B revenue (2024)\u003c\/li\u003e\n\u003cli\u003e28% domestic market share (2024)\u003c\/li\u003e\n\u003cli\u003e1–2% market CAGR\u003c\/li\u003e\n\u003cli\u003eSeasonal Q4–Q1 sales peaks\u003c\/li\u003e\n\u003cli\u003e~22% gross margin; defensive marketing\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eIldong’s high‑margin cash cows: Aronamin, gastro, antibiotics, OTC fuel R\u0026amp;D\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eIldong’s cash cows (Aronamin, gastro drugs, legacy antibiotics, OTC cold range) deliver steady high-margin cash: Aronamin KRW80B sales (2024), gastro KRW45B, antibiotics 18% group revenue, OTC KRW75B; margins 22–68%, low promo\/capex, market CAGRs 1–2% (2020–24), funding ~60% central R\u0026amp;D.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eProduct\u003c\/th\u003e\n\u003cth\u003e2024 Sales\u003c\/th\u003e\n\u003cth\u003eMarket share\u003c\/th\u003e\n\u003cth\u003eMargin\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eAronamin\u003c\/td\u003e\n\u003ctd\u003eKRW80B\u003c\/td\u003e\n\u003ctd\u003e45%\u003c\/td\u003e\n\u003ctd\u003e~60%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGastro\u003c\/td\u003e\n\u003ctd\u003eKRW45B\u003c\/td\u003e\n\u003ctd\u003e~18%\u003c\/td\u003e\n\u003ctd\u003e~68%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAntibiotics\u003c\/td\u003e\n\u003ctd\u003e-\u003c\/td\u003e\n\u003ctd\u003e18% group\u003c\/td\u003e\n\u003ctd\u003e~22%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOTC cold\u003c\/td\u003e\n\u003ctd\u003eKRW75B\u003c\/td\u003e\n\u003ctd\u003e28%\u003c\/td\u003e\n\u003ctd\u003e~22%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003ePreview = Final Product\u003c\/span\u003e\u003cbr\u003eIldong Pharmaceuticals BCG Matrix\u003c\/h2\u003e\n\u003cp\u003eThe file you're previewing is the exact Ildong Pharmaceuticals BCG Matrix you'll receive after purchase—fully formatted, no watermarks, and ready for strategic use in presentations or planning.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"MatrixBCG","offers":[{"title":"Default Title","offer_id":56747873468793,"sku":"ildong-bcg-matrix","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0911\/3554\/1625\/files\/ildong-bcg-matrix.png?v=1772202484","url":"https:\/\/matrixbcg.com\/products\/ildong-bcg-matrix","provider":"MatrixBCG","version":"1.0","type":"link"}